Searchable abstracts of presentations at key conferences in endocrinology

ea0013s75 | Pharmacological aspects of appetite control | SFEBES2007

The obesity pipeline: current strategies in the development of anti-obesity drugs

Cooke Dunstan , Bloom Steve

Obesity is a complex condition associated with numerous increased health risks caused by reduced physical activity and an increased consumption of energy-dense foods. It affects all ages and socio-economic groups, and is rising to global epidemic proportions.Lifestyle changes in diet and physical activity are capable of treating all but the severest cases of obesity, although low compliance is fuelling interest in effective therapies, including gastroint...

ea0065p220 | Metabolism and Obesity | SFEBES2019

GLP-1/Glucagon dual agonist affects amino acid metabolism

Scott Rebecca , Hope David , Owen Bryn , Bloom Steve , Tan Tricia

Background: GLP-1/glucagon dual agonists are being developed as treatments for obesity due to their combined effect of reducing food intake while increase energy expenditure. Though the effect of the dual agonist on carbohydrate and lipid metabolism is well studied, little is known about the effects on protein metabolism. This study aimed to examine the acute and chronic effects of the GLP-1/glucagon dual agonist on amino acid metabolism.Methods: The lon...

ea0044p137 | Neoplasia, cancer and late effects | SFEBES2016

The effects of proton pump inhibitor therapy on neuroendocrine tumour biomarkers

Constantinou Christoforos , Hill Neil , Bloom Steve , Murphy Kevin , Bech Paul

Introduction: Neuroendocrine tumours (NETs) comprise a heterogeneous group of tumours that constitute a diagnostic and therapeutic challenge. The most commonly used general NET circulating biomarker is Chromogranin A (CgA). CgA is elevated under other circumstances, notably by the use of Proton Pump Inhibitors (PPIs) and possibly via a gastrin-mediated mechanism. Chromogranin B (CgB) and Cocaine- and Amphetamine-Regulated transcript (CART) are two less commonly used NET biomar...

ea0034p199 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2014

The effect of L-cysteine on appetite in humans

Amin Anjali , Agahi Amy , Martin Niamh , Ghatei Mohamed , Bloom Steve , Murphy Kevin

High protein diets suppress appetite and facilitate weight loss, but are difficult to adhere to. Understanding the mechanisms by which protein suppresses appetite may establish targets for more acceptable interventions to treat or prevent obesity. Of particular interest is the concept of functional foods or novel products, which aim to potentiate satiety.Receptor systems that respond to amino acids have been identified. However, the specific mechanisms r...

ea0025p131 | Diabetes, metabolism and cardiovascular | SFEBES2011

Interactions between glucagon and GLP-1 in neuronal pathways affecting food intake

Parker Jennifer , Simpson Katherine , Minnion James , Field Ben , Ghatei Mohammad , Bloom Steve

Glucagon is released from α-cells in the pancreatic islets and is best known for its role in glucose homeostasis. Glucagon/GLP-1 receptor co-agonists have recently been shown to improve glucose homeostasis and reduce body weight in diet-induced obese mice. Glucagon receptor agonism increases energy expenditure while the GLP-1 receptor agonism prevents glucagon-induced hyperglycemia. Peripherally administered glucagon is also capable of reducing food intake, and glucagon n...

ea0025p132 | Diabetes, metabolism and cardiovascular | SFEBES2011

The effect of environmental enrichment on food intake, body weight and the HPA axis in laboratory rats

Beale Kylie , Harrison Eleanor , Smith Kirsty , Kerton Angela , Ghatei Mohammad , Bloom Steve , Murphy Kevin

Laboratory rats are commonly used to study energy homeostasis. To accurately record food intake or energy expenditure it is necessary to house rats individually, which can be stressful for social animals. Environmental enrichment may reduce stress and improve welfare in laboratory rodents. However, the effect of environmental enrichment on food intake and thus experimental outcome in rats is unknown. We aimed to determine the effect of environmental enrichment on food intake, ...

ea0015p209 | Neuroendocrinology and behaviour | SFEBES2008

The physiological response of Peptide YY following orlistat

Bhogal Randip S , Roux Carel W Le , Ahweyevu Rukevwe A , Bloom Steve R , Ghatei Mohammad A

Background: Orlistat is a lipase inhibitor used in the treatment of obesity. Recent published work has shown that orlistat may have a role in affecting the release of appetite regulating gastrointestinal derived peptides. However, the precise effect of orlistat on these hormones remains uncertain. This study aimed to evaluate the short-term effects of orlistat with a high fat meal on levels of plasma Peptide YY (PYY) and on appetite.Methods: Ethical perm...

ea0025p154 | Diabetes, metabolism and cardiovascular | SFEBES2011

Over-expression of iodothyronine deiodinase III in the hypothalamic VMN as a potential model of local hypothyroidism

Greenwood Hannah , Counsell John , Richardson Errol , Dhillo Waljit , Boelen Anita , Williams Graham , Bassett Duncan , Bloom Steve , Gardiner James

The hypothalamo-pituitary–thyroid (HPT) axis maintains controlled systemic levels of thyroid hormone (TH). This is achieved through negative feedback via the hypothalamic arcuate and paraventricular nuclei. The effects of thyroid hormone in other hypothalamic nuclei are yet to be elucidated. Administration of triiodothyronine (T3, thyroid hormone) into the hypothalamic ventromedial nucleus (VMN) increases food intake in rats. Thyroid hormone activation and inac...

ea0053cd2.2 | Case Discussions: complex clinical cases 2.0 | OU2018

Poor responsiveness after bariatric surgery: clinical and eating behaviour characteristics

Perez-Pevida Belen , Aldhwayanand Madhawi , Gibson Rachel , Scholtz Samantha , Miras Alexander D , McGlone Emma , Kamocka Anna , Khan Omar , Greener Veronica , McGowan Barbara , Rubino Francesco , Bloom Steve , Tan Tricia

Background: Bariatric surgery has been proven to produce substantial weight loss and amelioration of metabolic syndrome-associated co-morbidities. However, at five-year follow-up, only 20–40% of patients maintain diabetes remission and 40% of patients return to their baseline weight. The limiting factor in treating refractory diabetes following obesity surgery is the lack of knowledge about its aetiology.Aims: Evaluate the eating pattern and clinica...

ea0048oc3 | Oral Communications | SFEEU2017

The early improvement of glycaemia following RYGB can be mimicked by a Very Low Calorie Diet in obese volunteers with diabetes

Behary Preeshila , Tharakan George , Al-Najim Werd , Brown Adrian , Miras Alexander , Stoenchev Kostadin , Chahal Harvinder , Purkayastha Sanjay , Moorthy Krishna , Ahmed Ahmed , Bloom Steve , Tan Tricia

Introduction: Improvement in glycaemia is observed early after Roux-en-Y Gastric Bypass surgery (RYGB) in patients with diabetes. Commonly cited mechanisms to account for these changes include the elevation of gut hormones, increase in bile acids levels, changes in the gut microbiota and calorie restriction. Calorie restriction is believed to play a role in improving hepatic insulin sensitivity and reduce hepatic glucose output early after RYGB, in the context of non-significa...